Rudi Gruber

415 total citations
10 papers, 344 citations indexed

About

Rudi Gruber is a scholar working on Immunology, Infectious Diseases and Genetics. According to data from OpenAlex, Rudi Gruber has authored 10 papers receiving a total of 344 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Immunology, 3 papers in Infectious Diseases and 3 papers in Genetics. Recurrent topics in Rudi Gruber's work include Monoclonal and Polyclonal Antibodies Research (2 papers), Inflammatory Bowel Disease (2 papers) and Glycosylation and Glycoproteins Research (1 paper). Rudi Gruber is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (2 papers), Inflammatory Bowel Disease (2 papers) and Glycosylation and Glycoproteins Research (1 paper). Rudi Gruber collaborates with scholars based in Germany, United States and Sweden. Rudi Gruber's co-authors include Yuji Takeda, Ola Winqvist, Michael Eberhardson, Abbi R. Saniabadi, Hiroyuki Hanai, Robert Löfberg, Christian Jaeger, Katrin Uhlig, Matthias Mack and M Schattenkirchner and has published in prestigious journals such as Annals of the Rheumatic Diseases, Advances in experimental medicine and biology and Clinical & Experimental Immunology.

In The Last Decade

Rudi Gruber

10 papers receiving 333 citations

Peers

Countries citing papers authored by Rudi Gruber

Since Specialization

Citations

This map shows the geographic impact of Rudi Gruber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rudi Gruber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rudi Gruber more than expected).

Fields of papers citing papers by Rudi Gruber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rudi Gruber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rudi Gruber. The network helps show where Rudi Gruber may publish in the future.

Co-authorship network of co-authors of Rudi Gruber

This figure shows the co-authorship network connecting the top 25 collaborators of Rudi Gruber. A scholar is included among the top collaborators of Rudi Gruber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rudi Gruber. Rudi Gruber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

#	Work	Indexed citations
1	Binding of phosphatidylserine‐positive microparticles by PBMCs classifies disease severity in COVID‐19 patients 2021 ·Journal of Extracellular Vesicles ·Lisa Rausch, (unknown), Martina Schifferer, Elena Winheim, Rudi Gruber, (unknown), (unknown), Johannes C. Hellmuth, Clemens Scherer, Maximilian Muenchhoff, (unknown), Michael S. von Bergwelt‐Baildon, Mikael Simons, Tobias Straub, Anne Krug, Jan Kranich, Thomas Brocker	26
2	Pooling for SARS-CoV-2-testing: comparison of three commercially available RT-qPCR kits in an experimental approach 2021 ·Clinical Chemistry and Laboratory Medicine (CCLM) ·(unknown), Jürgen J. Wenzel, Rudi Gruber, Andreas Ambrosch	7
3	The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review 2010 ·Clinical & Experimental Immunology ·Hiroyuki Hanai, Yuji Takeda, Michael Eberhardson, Rudi Gruber, Abbi R. Saniabadi, Ola Winqvist, Robert Löfberg	78
4	Influence of peptidylarginine deiminase type 4 genotype and shared epitope on clinical characteristics and autoantibody profile of rheumatoid arthritis 2008 ·Annals of the Rheumatic Diseases ·Berthold Hoppe, Thomas Häupl, Karl Egerer, Rudi Gruber, H. Kiesewetter, A. Salama, Gerd R Burmester, Thomas E. Dorner	27
5	Serum Antibodies in First-Degree Relatives of Patients with IBD: A Marker of Disease Susceptibility? A Follow-Up Pilot-Study after 7 Years 2005 ·Digestion ·Helga‐Paula Török, Jürgen Glas, (unknown), Rudi Gruber, Michael Osthoff, (unknown), (unknown), Thomas Mussack, Matthias Folwaczny, C Folwaczny	13
6	Inflammatory Bowel Disease-Specific Autoantibodies in HLA-B27-Associated Spondyloarthropathies: Increased Prevalence of ASCA and pANCA 2004 ·Digestion ·Helga‐Paula Török, Jürgen Glas, Rudi Gruber, (unknown), Christa Strasser, (unknown), Elisabeth Märker‐Hermann, C Folwaczny	38
7	Anti-self antibodies selected from a human IgD heavy chain repertoire: a novel approach to generate therapeutic human antibodies against tumor-associated differentiation antigens 2001 ·Cancer Immunology Immunotherapy ·Tobias Raum, Rudi Gruber, Gert Riethmüller, Peter Kufer	34
8	Predominance of mononuclear cells expressing the chemokine receptor CCR5 in synovial effusions of patients with different forms of arthritis 1999 ·Arthritis & Rheumatism ·Matthias Mack, (unknown), Rudi Gruber, Christian Jaeger, Josef Cihak, (unknown), (unknown), M. Stangassinger, Katrin Uhlig, M Schattenkirchner, (unknown)	115
9	Lack of Protection from HIV infection by the Mutant HIV Coreceptor CCR5 in Intravenously HIV Infected Hemophilia Patients 1998 ·Immunobiology ·Antje Malo, (unknown), Johannes R. Bogner, Rudi Gruber, Wolfgang Schramm, F. D. Goebel, G. Riethmüller, Rudolf Wank	4
10	Detection of Antineutrophil Cytoplasmatic Antibodies (ANCA) and their Association with other Autoantibodies in Patients with Hepatobiliary Disorders 1993 ·Advances in experimental medicine and biology ·Rudi Gruber, Carsten Brockmeyer, (unknown), (unknown), (unknown), Gert Riethmüller	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact